FIG. 6A



Sample Name
10 psi.fcs
18 psi.fcs
14 psi.fcs
12 psi.fcs
10 psi.fcs
Endo.fcs
NC.fcs
BL1-A :: 70kDa dextran-A

FIG. 6B



Estimated viability (%)
100
90
80
70
60
50
40
30
20
10
0
NC
Endo
10 psi
12 psi
14 psi
16 psi
18 psi

FIG. 10



Naïve
0.49%
Challenge Control
8.13%
Tolerance Control
1.38%
RBC-Endo
11.7%
RBC-SQZ
1.45%
Donor T cells (CD45.2)
Recipient T Cells (CD45.1)
7.07%
Naïve
76.0%
Challenge Control
64.2%
Tolerance Control
75.8%
RBC-Endo
57.1%
RBC-SQZ
IFN-γ
CD44

FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 6A



Sample Name
18 psi.fcs
16 psi.fcs
14 psi.fcs
12 psi.fcs
10 psi.fcs
Endo.fcs
NC.fcs
10^1
10^3
10^5
BL1-A :: -70kDa dextran-A

FIG. 6B



Estimated viability (%)
100
90
80
70
60
50
40
30
20
10
0
NC
Endo
10 psi
12 psi
14 psi
16 psi
18 psi

FIG. 10



Naïve
0.49%
Challenge Control
8.13%
Tolerance Control
1.38%
RBC-Endo
11.7%
RBC-SQZ
1.45%
7.07%
76.0%
64.2%
75.8%
57.1%
Donor T Cells (CD45.2)
Recipient T Cells (CD45.1)
IFN-γ
CD44

FIG. 11A



FIG. 11B




FIG. 12A




FIG. 12B

